Get started
Author

David J.P. Critchley

Observed names: Critchley Djp., D. Critchley, D. J. Critchley, D. J. P. Critchley, D.J.P. Critchley, David Critchley, David J. Critchley, David John Critchley
ORCID: 0000-0003-1043-7794
Observed ORCID: 0000-0003-1043-7794
OpenAlex ID: A5055294109
Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist
1995 · Allan Fletcher, Elaine A. Forster, et al. · Behavioural Brain Research · 530
Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy
2008 · Emilio Perucca, James Cloyd, et al. · Epilepsia · 261
PDF
Species variation in hepatic aldehyde oxidase activity
1987 · C. Beedham, S. E. Bruce, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 96
Substrate Specificity of Human Liver Aldehyde Oxidase toward Substituted Quinazolines and Phthalazines: A Comparison with Hepatic Enzyme from Guinea Pig, Rabbit, and Baboon
1995 · C. Beedham, D.J.P. Critchley, et al. · Archives of Biochemistry and Biophysics · 94
A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects
2020 · Julie Crockett, David Critchley, et al. · Epilepsia · 83
PDF
Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
2020 · Philip N. Patsalos, Jerzy P. Szaflarski, et al. · Epilepsia · 71
PDF
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
2020 · Elinor Ben-Menachem, Boudewijn Gunning, et al. · CNS Drugs · 68
1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases
1990 · Christine Beedham, Sally E. Bruce, et al. · Biochemical Pharmacology · 39
A Phase 1 Open‐Label, Fixed‐Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects
2021 · Ching Thai, Bola Tayo, et al. · Clinical Pharmacology in Drug Development · 37
Inhibition of 8-OH-DPAT-induced elevation of plasma corticotrophin by the 5-HT1A receptor antagonist WAY100635
1994 · David J.P. Critchley, Kirstie J. Childs, et al. · European Journal of Pharmacology · 37
Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study
2016 · Alexis Arzimanoglou, Jose A. Ferreira, et al. · European Journal of Paediatric Neurology · 32
PDF
Biotransformation of carbazeran in guinea pig: Effect of hydralazine pretreatment
1994 · D. J. P. Critchley, D. J. Rance, et al. · Xenobiotica · 26
Pharmacokinetic Drug‐Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial
2023 · Louise Wray, Joris Berwaerts, et al. · Clinical Pharmacology in Drug Development · 25
PDF
Subcellular localisation of guinea pig hepatic molybdenum hydroxylases
1992 · David J.P. Critchley, David J. Rance, et al. · Biochemical and Biophysical Research Communications · 24
Investigation of the Metabolism of Rufinamide and Its Interaction with Valproate
2011 · Eric T. Williams, J. Eric Carlson, et al. · Drug Metabolism Letters · 23
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820
2008 · Ron J. Keizer, Miren K. Zamacona, et al. · Investigational New Drugs · 21
Comparisons between the effects of 5-HT and dl-fenfluramine on food intake and gastric emptying in the rat
1995 · David Critchley, Colin T. Dourish, et al. · Pharmacology Biochemistry and Behavior · 20
Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison
2016 · Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, et al. · Investigational New Drugs · 15
Supporting the recommended paediatric dosing regimen for rufinamide in Lennox–Gastaut syndrome using clinical trial simulation
2010 · M. Marchand, E. Fuseau, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 13
Effects of the selective 5-HT1A receptor antagonist WAY100135 and its enantiomers on 8-OH-DPAT-induced hyperglycaemia in conscious rats
1994 · David J.P. Critchley, Vicki C. Middlefell, et al. · European Journal of Pharmacology · 13
Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects
2011 · David John Critchley, Jagadeesh Aluri, et al. · Clinical Therapeutics · 9
Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol
2004 · H.J.G. Desirée van den Bongard, Rolf W. Sparidans, et al. · Investigational New Drugs · 6
Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy
2019 · David Critchley, Jerzy Szaflarski, et al. · Epilepsy & Behavior · 4
Drug-drug Interaction Studies with Coadministration of Cannabidiol (CBD) and Clobazam, Valproate, Stiripentol or Midazolam in Healthy Volunteers and Adults with Epilepsy
2019 · Jerzy Szaflarski, Philip Patsalos, et al. · Neuropediatrics · 1
1FC1.2 A Novel Rufinamide Oral Liquid/Suspension Formulation for Lennox-Gastaut Syndrome Patients
2011 · D. Critchley · European Journal of Paediatric Neurology · 1
Works count: 30
Citation count: 1,550
H-index: 17
I10-index: 20
Year
Topic
Type